Personalised mRNA cancer vaccine cuts melanoma return risk by 42%

A personalised mRNA vaccine, Intismeran, given with the immunotherapy drug Keytruda cut the risk of death or melanoma returning by 42% in a trial of 1,137 patients whose tumours had been surgically removed. It also lowered the risk of spread by 38% over two years. Makers MSD and Moderna are testing the approach in kidney, bladder and lung cancers.